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Abstract  
There is widespread agreement that PrEP must be considered as part of a comprehensive HIV prevention 
strategy for people who inject drugs. We consider two linked questions: how to ensure people have the 
necessary choices for comprehensive HIV prevention? how can research and scientific communities best 
support this? Recognising criminalization and human rights, and focusing on community centred, 
integration oriented research programmes is vital.   
The consensus across our commentary [1] and responses [2-4]  that  PrEP should form part of a 
comprehensive package of HIV prevention for People Who Inject Drugs (PWID) generates two linked 
questions: how can we ensure that PWID can access  all essential elements of comprehensive HIV 
prevention and have choices across them[2]? How can the research community best support this effort?  
 
Our central argument is that HIV prevention research and development strategy needs to not only 
coherently respond to the concerns and needs of affected and vulnerable communities, but also be 
developed and implemented in partnership with them [1]. We are not condemning PrEP and instead 
welcome its progress [1]. There is, however, a danger that if we as a scientific community continue 
research and development of PrEP in isolation we will sideline attention to existing interventions. The 
appropriate response is not to stop PrEP development, but to ensure our research strategy furthers the 
strengthening of rights based and comprehensive programming.  
 
Exploring how dominant HIV prevention strategies exclude specific groups is not polarising harm 
reduction and biomedical interventions [4]. Our argument represents the opposite: the current reality of 
strategy and provision of care for PWID is already polarized by excluding so many views; our analysis 
seeks to bring to the fore voices rarely heard and so place biomedical advance in a fuller context. The 
responses in this debate series suggest this synthesis is possible [2-4].  
 
How then to ensure PWID have the choice of PrEP alongside other HIV prevention interventions that are 
not yet implemented to scale? The foundation for our response must be recognition of the right to 
health for all human beings [5] and the increasing futility and collateral damage of the ‘war on drugs’ 
and criminalization of PWID [6]. In recognizing the often ignored crucial role of skilled community 
advocacy and leadership in battles for service access and harm reduction innovation [2, 7], community 
driven responses should be the focus for political action.  
 
How can the research and scientific community best support this effort? Theoretically and 
institutionally, we should work better to ensure community experiences are addressed in the design of 
research and as a focus for research questions.  Bruneau et al suggest [4] a series of implementation 
questions relating to integration. Responding also to emerging evidence for PrEP’s cost-effectiveness in 
combination with ART and OST [3, 8], we then suggest that future research be developed with 
integration and combination of interventions as organizing frameworks as a necessary response to 
concerns about implementation in isolation. To these questions we also add that research should 
explore how contexts of criminalization and persecution shape implementation and integration of PrEP; 
operational and health services research must be informed by in-depth critical social and political 
science.  
 
In conclusion, we seek to build on  the community views in the INPUD report [9], in seeking truly 
comprehensive rights based, community driven HIV prevention and exploring an appropriate role for 
PrEP within this framework. HIV prevention strategy must emphasise policy issues of decriminalizing 
drug use, engaging communities in decision making and fostering implementation of evidence-based 
interventions that remain grossly under-utilized. PrEP belongs in our arsenal but as with other 
intervention components we should not look to it as the panacea, nor can we afford to ignore legitimate 
concerns raised by the PWID community.  
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